NexMed Announces Encouraging Pre-Clinical Results Showing the Ability of the NexACT® Technology to Enhance the Bioavailabili...
11 May 2010 - 7:19AM
Business Wire
NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of
products based on the NexACT® technology, today announced data from
a pre-clinical study examining the subcutaneous delivery of
rituximab, the first FDA-approved therapeutic antibody for the
treatment of cancer in the United States. The study results showed
that animals receiving subcutaneous injections of rituximab,
incorporated with NexACT, demonstrated a 46% enhancement in
bioavailability over rituximab, alone.
Rituximab is a cancer medication that interferes with the
development of cancer cells, slowing their growth and spread in the
body. Delivered via intravenous infusion, rituximab is the active
drug in Rituxan®, currently marketed by Genentech and Biogen IDEC,
and prescribed to treat Non-Hodgkin's Lymphoma (NHL), Chronic
Lymphocytic Leukemia (CLL) and Rheumatoid Arthritis (RA).
Commenting on today’s news, Dr. Bassam Damaj, President and
Chief Executive Officer of NexMed, stated, “The ability of the
NexACT technology to successfully deliver rituximab subcutaneously
in a pre-clinical setting may open the door to improving the
delivery of other therapeutic antibodies, which the Company is in
the process of studying. The use of human or humanized monoclonal
antibodies, therapeutically, was a major breakthrough in the field
of medicine. If the NexACT technology can ultimately be shown to
lower the amount of antibody administered while improving the route
of delivery and minimizing side effects, NexACT could potentially
revolutionize the use of these drugs in the future. We look forward
to advancing our work in this area and to the further studies that
will be needed to validate these results in humans.”
About NexMed, Inc.
NexMed is the largest specialty CRO based in San Diego, CA and
is one of the industry's most experienced CROs for in vitro and in
vivo pharmacology services and research models. The Company’s goal
is to generate revenues from the growth of its Discovery
Pre-clinical CRO business, while aggressively seeking to monetize
its proprietary NexACT drug delivery technology through
out-licensing agreements with pharmaceutical and biotechnology
companies, worldwide. At the same time, NexMed is actively pursuing
partnering opportunities for its NexACT-based treatments for
onychomycosis, psoriasis, sexual dysfunction and cancer. For
further information on NexMed and its subsidiaries, visit the
following websites: http://www.nexmed.com or
http://www.bio-quant.com.
Rituxan® is a registered trademark of Biogen IDEC.
Forward-Looking Statement Safe
Harbor
Statements under the Private Securities Litigation Reform Act:
with the exception of the historical information contained in this
release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may
individually or mutually impact the matters herein described for a
variety of reasons that are outside the control of the Company
including but not limited to its ability to obtain and/or NexMed’s
ability to pursue its development strategy and the ability to
replicate results from its preclinical research with the NexACT
technology in later human clinical studies.
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From May 2024 to Jun 2024
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From Jun 2023 to Jun 2024